
Neurologist

No OPD information available
Seizures
Absence Seizure
Epilepsy
Generalized Tonic-Clonic Seizure
Hashimoto Thyroiditis
Juvenile Myoclonic Epilepsy
Encephalitis
Photosensitive Epilepsy
Status Epilepticus
Anti-NMDA Receptor Encephalitis
Conversion Disorder
Creutzfeldt-Jakob Disease
Epilepsy Juvenile Absence
Genetic Epilepsy with Febrile Seizures Plus (GEFS+)
Hyperventilation
Pseudotumor Cerebri Syndrome
Udaya K. Seneviratne is a doctor who helps people with different health issues like seizures, epilepsy, and other brain-related conditions. He is skilled in treating various types of seizures such as absence seizures and generalized tonic-clonic seizures. He also deals with conditions like Hashimoto thyroiditis, encephalitis, and conversion disorder.
Dr. Seneviratne is known for his expertise in treating juvenile myoclonic epilepsy, photosensitive epilepsy, and status epilepticus. He is also experienced in managing complex conditions like anti-NMDA receptor encephalitis, Creutzfeldt-Jakob disease, and genetic epilepsy with febrile seizures plus (GEFS+).
Patients trust Dr. Seneviratne because he communicates well with them, explaining their conditions and treatment options clearly. He stays updated on the latest medical knowledge and research to provide the best care possible. He works closely with other medical professionals, collaborating to ensure patients receive comprehensive and coordinated care.
Dr. Seneviratne's work has had a positive impact on many patients' lives, improving their health and quality of life. He has published research on personalized medication selection for epilepsy and has conducted clinical trials to evaluate new treatments for seizures.
In summary, Udaya K. Seneviratne is a dedicated and skilled doctor who specializes in treating seizures and epilepsy. He is committed to providing high-quality care, staying informed about the latest advancements in his field, and working collaboratively with other healthcare professionals to benefit his patients.
Enrollment Status: Completed
Published: May 14, 2024
Intervention Type: Drug
Study Drug: YKP3089
Study Phase: Phase 3
